Summit Therapeutics PLC ((SMMT)), Summit Therapeutics ((GB:SUMM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Summit Therapeutics PLC, in collaboration with Akeso, is conducting a Phase II clinical trial titled A Phase II Study of AK112 With or Without AK117 for Patients With Metastatic Colorectal Cancer. The study aims to evaluate the efficacy, safety, and pharmacokinetics of AK112, with or without AK117, in patients with metastatic colorectal cancer who are not candidates for surgery. This research is significant as it explores potential new treatment options for a challenging cancer type.
The trial tests the drugs AK112 and AK117, both administered via intravenous infusion. These drugs are being assessed for their ability to treat metastatic colorectal cancer, either alone or in combination with standard chemotherapy regimens like XELOX and FOLFOXIRI.
The study is designed as an interventional trial with a randomized allocation and a parallel intervention model. There is no masking involved, and the primary purpose is treatment. This straightforward design helps in assessing the direct impact of the interventions.
The trial began on June 27, 2022, with an estimated completion date in August 2025. These timelines are crucial for investors as they indicate when results might influence market dynamics. The last update was submitted on August 6, 2025, suggesting ongoing progress.
This clinical update could potentially impact Summit Therapeutics’ stock performance positively, as successful results may lead to new treatment approvals and market opportunities. Investors should also consider the competitive landscape, as advancements in colorectal cancer treatments are highly sought after in the pharmaceutical industry.
The study is currently recruiting, with further details available on the ClinicalTrials portal.